Article
Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
All News
Article
Two biologic therapies showed promise in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in a retrospective European study.
Article
A French Vasculitis Study Group analysis of their granulomatosis with polyangiitis (GPA) reveals that after 10 years, only 7% of GPA patients achieved sustained remission off therapy (SROT) and have never relapsed.
Article
JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.
Article
Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:
Article
Lancet Infectious Disease has reviewed the epidemiology, causes, clinical features, and current treatment for the multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19, noting severe organ damage can occur pediatric COVID-19 patients who are severely ill.&
Article
JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has approved tocilizumab as a first-line glucocorticoid-sparing agent.
Article
A systematic review and meta-analysis of 68 diagnostic cohort studies (14 037 patients) suggests that no one feature is more impactful that the combination of symptoms, signs, and laboratory tests to diagnose the presence giant cell arteritis (GCA).
Article
Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.
Article
An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).
Bella Mehta
Tweet
#ACR20 year in review by @JYazdanyMD latest data PEXIVAS and SEMIRA trials on corticosteroids - would you change your clinical practice to minimize even low dose Corticosteroids in RA and Vasculitis? @RheumNow
https://t.co/l7PTyANpjq
https://t.co/MRGbsjaGae
alexa meara
Tweet
APS induced by CoViD-19: plenary session 1- another reason we need to break down the silos and involve rheumatologist more! Should we be using anticoagulation in these patients? #ACR20 @RheumNow @OSUWexMed
Peter Nash
Tweet
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need
KenWarringtonMD
Tweet
Exciting to hear about 5 trials for #GCA
1. ABAGART (#Abatacept)
2. METOGIA (#tocilizumab vs MTX)
3. SELECT (#upadacitinib)
4. MAVRILIMUMAB (#gmcsf i)
5. TiTIAN (#secukinumab)
@VasculitisFound #vasculitis #vcrc https://t.co/DVvG5Ekfu9
Dr. John Cush
Tweet
There have been many cases of Kawasaki vasculitis in kids ith COVID-19; now Lg vessel vasculitis in 79 yo Japanese man w/ COVID-19 pneumonia, CRP 17.7 mg/dL, spiking fevers and CTA and FDG-PET evid of aortic and LVV, neg ANCA, nl IgG4, but was HLA-DR4+. https://t.co/UpL4Z1qK2p
Dr. John Cush
Tweet
In elderly AAV, initial steroid dose should be rapidly reduced be required to safe outcomes. Study of 179 AAV pts 80yrs old w/ high Birmingham Vasculitis Score 16.1. 94% MPO+, 6% PR3+, Serious infections seen in high-dose Pred vs low dose (43% vs. 22%) https://t.co/mZbtKvPUIX
Dr. John Cush
Tweet
European collaborative study of eosinophilic granulomatosis with polyangiitis (EGPA) Rx w/ RTX, mepolizumab or omalizumab (OMA). MEP > RTX > OMA. Mepolizumab was highly effective in GC‐dependent asthma. https://t.co/fi8pjnJO03
k dao
Tweet
"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis."
Image shows when to start/stop PJP prophylaxis
Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
Dr. John Cush
Tweet
Case series compared 247 pregnancies in IgA Vasculitis patients vs 556 control pregnancies showing IgA Vasculitis had no effect on fertility and did not induce flares. But IgAV had more spont. abortions, gestational HTN, preterm delivery. https://t.co/CCG2v6sMe1
Peter Nash
Tweet
@RheumNow its time we stopped “seroneg RA” which are many diseases, like ANCA pos Vasculitis we should have ACPA pos RA and others - how many viral arthritides in our country “doing great” on SZP, PLAQ, or low dose MTX and reluctant to stop? #RA #Seronegative
